BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300
55 results:

  • 1. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
    Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Resveratrol affects ccRCC cell senescence and macrophage polarization by regulating the stability of CCNB1 by RBM15.
    Chen Z; Liu C; Ye T; Zhang Y; Chen Y
    Epigenomics; 2023 Sep; 15(18):895-910. PubMed ID: 37909116
    [No Abstract]    [Full Text] [Related]  

  • 3. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
    Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
    Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
    Shao IH; Peng PH; Wu HH; Chen JL; Lai JC; Chang JS; Wu HT; Wu KJ; Pang ST; Hsu KW
    Cancer Med; 2023 Apr; 12(8):9788-9801. PubMed ID: 36847128
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Molecular subtypes based on metabolic genes are potential biomarkers for predicting prognosis and immune responses of clear cell renal cell carcinoma.
    Wang Y; Ji H; Zhu B; Xing Q; Xie H
    Eur J Immunol; 2023 Jan; 53(1):e2250105. PubMed ID: 36367018
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment.
    Jiang Z; Zhang W; Zeng Z; Tang D; Li C; Cai W; Chen Y; Li Y; Jin Q; Zhang X; Yin L; Liu X; Xu Y; Dai Y
    Front Immunol; 2022; 13():926461. PubMed ID: 36311770
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.
    Sahu DK; Singh N; Das M; Rawat J; Gupta DK
    Pediatr Surg Int; 2022 Nov; 38(11):1601-1617. PubMed ID: 36107237
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
    Tamukong PK; Kuhlmann P; You S; Su S; Wang Y; Yoon S; Gong J; Figlin RA; Janes JL; Freedland SJ; Halabi S; Small EJ; Rini BI; Kim HL
    Urol Oncol; 2022 Nov; 40(11):495.e1-495.e10. PubMed ID: 35973929
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The SWI/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-β signaling.
    Cui H; Yi H; Bao H; Tan Y; Tian C; Shi X; Gan D; Zhang B; Liang W; Chen R; Zhu Q; Fang L; Gao X; Huang H; Tian R; Sperling SR; Hu Y; Chen W
    Nat Commun; 2022 Aug; 13(1):4680. PubMed ID: 35945219
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11.
    Zeng X; Chen K; Li L; Tian J; Ruan W; Hu Z; Peng D; Chen Z
    Free Radic Biol Med; 2022 May; 184():135-147. PubMed ID: 35381326
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Safety, efficacy, and mid-term oncological outcomes of computed tomography-guided cryoablation of T1 renal cancer.
    Duus LA; Junker T; Rasmussen BS; Bojsen JA; Pedersen AL; Anthonsen A; Lund L; Pedersen M; Graumann O
    Acta Radiol; 2023 Feb; 64(2):814-820. PubMed ID: 35297745
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
    Zhang C; Lu X; Huang J; He H; Chen L; Liu Y; Wang H; Xu Y; Xing S; Ruan X; Yang X; Chen L; Xu D
    Clin Transl Med; 2021 Feb; 11(2):e328. PubMed ID: 33634984
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
    Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules.
    Wang Z; Li K; Chen W; Wang X; Huang Y; Wang W; Wu W; Cai Z; Huang W
    Cell Mol Life Sci; 2020 Sep; 77(17):3441-3452. PubMed ID: 31838573
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
    Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
    Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.
    Williamson SR; Rao P; Hes O; Epstein JI; Smith SC; Picken MM; Zhou M; Tretiakova MS; Tickoo SK; Chen YB; Reuter VE; Fleming S; Maclean FM; Gupta NS; Kuroda N; Delahunt B; Mehra R; Przybycin CG; Cheng L; Eble JN; Grignon DJ; Moch H; Lopez JI; Kunju LP; Tamboli P; Srigley JR; Amin MB; Martignoni G; Hirsch MS; Bonsib SM; Trpkov K
    Am J Surg Pathol; 2018 Sep; 42(9):1253-1261. PubMed ID: 29878933
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2.
    Cocco E; Leo M; Canzonetta C; Di Vito S; Mai A; Rotili D; Di Napoli A; Vecchione A; De Nunzio C; Filetici P; Stoppacciaro A
    Clin Epigenetics; 2018; 10():44. PubMed ID: 29632619
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. NOX4 functions as a mitochondrial energetic sensor coupling cancer metabolic reprogramming to drug resistance.
    Shanmugasundaram K; Nayak BK; Friedrichs WE; Kaushik D; Rodriguez R; Block K
    Nat Commun; 2017 Oct; 8(1):997. PubMed ID: 29051480
    [TBL] [Abstract] [Full Text] [Related]  

  • 20.
    Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
    Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.